1992
Eczacıbaşı's 50th anniversary became the beginning of a new period of growth for the Group with five new investments.

The modern pharmaceutical complex of Eczacıbaşı Pharmaceuticals Industry in Lüleburgaz started production with an annual production capacity of 150 million units.
 
2005
Eczacıbaşı Group renewed its logo having been used since 1993. The new logo using orange and warm gray colours with highlighting Eczacıbaşı's "e" aims to reflect the Group's innovativeness, dynamic structure, humanity and exemplary position in the society. The new three-dimensional logo was designed in accordance with the latest understanding in the field of visual design and today's digital technologies.
 
2008
Eczacıbaşı Pharmaceuticals Marketing signed agreements with Medical Enzymes and Vical with its aim to be the leader to introduce high-tech products to Turkish market especially in critical areas with limited treatment options.
 
2011
It collaborated with Juvisé Pharmaceuticals, a rising star in the pharmaceutical industry of France, in the field of psychiatric medicine. The first step of the collaboration was the licensing agreement of an antidepressant used for the treatment of mental disorders accompanied by the conditions such as anxiety, restlessness, lack of concentration and especially psychosomatic disorders.
 
2016
Following the restructuring of Baxter's biotechnological innovative products division under a new company called Baxalta, Eczacıbaşı-Baxter's Hospital Products and Biosurgery Departments joined Eczacıbaşı Pharmaceuticals Marketing. Thus, EPM became an organization that covers all the service areas in the health sector.

Eczacıbaşı signed an agreement also with Zydus Cadila, one of the leading healthcare organizations in the world, on putting a portfolio of biotechnological products on the market in Turkey.
 
1989
Eczacıbaşı Pharmaceuticals Marketing (EPM/EIP) was established. The sales and marketing activities of Eczacıbaşı Pharmaceuticals Industry have been carried out by EPM since this year.
 
1993
The founder of Eczacıbaşı Group and the Honorary Chairman of the Board of Directors of Eczacıbaşı Holding, Dr. Nejat F. Eczacıbaşı passed away.
 
2007
Eczacıbaşı Pharmaceuticals Industry transferred 75% of its shares in Eczacıbaşı Health Products and Eczacıbaşı Özgün Kimya to Zentiva N.V., one of the leading generic drug companies in Europe.
 
2009
All shares of Eczacıbaşı Group in Eczacıbaşı-Zentiva Health Products and Eczacıbaşı-Zentiva Chemical Products were transferred to Zentiva N.V.. Eczacıbaşı Pharmaceuticals Marketing's Vicks brand was awarded with the grand prize in two categories by FARMASKOP AWARDS which rewards the innovative communication in the health sector.
 
2014
P&G (Procter & Gamble), one of the leading companies in the fast-moving consumer goods sector, signed an important collaboration with Eczacıbaşı Pharmaceuticals Marketing within the scope of its growth target in the healthcare group. With this collaboration, P&G aims to offer its products to more pharmacy consumers.
1989
Eczacıbaşı Pharmaceuticals Marketing (EPM/EIP) was established. The sales and marketing activities of Eczacıbaşı Pharmaceuticals Industry have been carried out by EPM since this year.
1992
Eczacıbaşı's 50th anniversary became the beginning of a new period of growth for the Group with five new investments.

The modern pharmaceutical complex of Eczacıbaşı Pharmaceuticals Industry in Lüleburgaz started production with an annual production capacity of 150 million units.
1993
The founder of Eczacıbaşı Group and the Honorary Chairman of the Board of Directors of Eczacıbaşı Holding, Dr. Nejat F. Eczacıbaşı passed away.
2005
Eczacıbaşı Group renewed its logo having been used since 1993. The new logo using orange and warm gray colours with highlighting Eczacıbaşı's "e" aims to reflect the Group's innovativeness, dynamic structure, humanity and exemplary position in the society. The new three-dimensional logo was designed in accordance with the latest understanding in the field of visual design and today's digital technologies.
2007
Eczacıbaşı Pharmaceuticals Industry transferred 75% of its shares in Eczacıbaşı Health Products and Eczacıbaşı Özgün Kimya to Zentiva N.V., one of the leading generic drug companies in Europe.
2008
Eczacıbaşı Pharmaceuticals Marketing signed agreements with Medical Enzymes and Vical with its aim to be the leader to introduce high-tech products to Turkish market especially in critical areas with limited treatment options.
2009
All shares of Eczacıbaşı Group in Eczacıbaşı-Zentiva Health Products and Eczacıbaşı-Zentiva Chemical Products were transferred to Zentiva N.V..

Eczacıbaşı Pharmaceuticals Marketing's Vicks brand was awarded with the grand prize in two categories by FARMASKOP AWARDS which rewards the innovative communication in the health sector.
2011
It collaborated with Juvisé Pharmaceuticals, a rising star in the pharmaceutical industry of France, in the field of psychiatric medicine. The first step of the collaboration was the licensing agreement of an antidepressant used for the treatment of mental disorders accompanied by the conditions such as anxiety, restlessness, lack of concentration and especially psychosomatic disorders.
2014
P&G (Procter & Gamble), one of the leading companies in the fast-moving consumer goods sector, signed an important collaboration with Eczacıbaşı Pharmaceuticals Marketing within the scope of its growth target in the healthcare group. With this collaboration, P&G aims to offer its products to more pharmacy consumers.
2016
Following the restructuring of Baxter's biotechnological innovative products division under a new company called Baxalta, Eczacıbaşı-Baxter's Hospital Products and Biosurgery Departments joined Eczacıbaşı Pharmaceuticals Marketing. Thus, EPM became an organization that covers all the service areas in the health sector.

Eczacıbaşı signed an agreement also with Zydus Cadila, one of the leading healthcare organizations in the world, on putting a portfolio of biotechnological products on the market in Turkey.